- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Ro Launches Eli Lilly's KwikPen® for Zepbound®, Offering Patients More Convenient Treatment
The prefilled, multi-dose pen provides an easier way for patients to take the most effective GLP-1 medication.
Apr. 2, 2026 at 5:27pm
Got story updates? Submit your updates here. ›
Ro, the leading direct-to-patient healthcare company, has announced a partnership with Eli Lilly to launch the recently FDA-approved Zepbound® (tirzepatide) KwikPen® nationwide on its platform. The new prefilled, multi-dose pen offers patients a more convenient way to take the most effective GLP-1 medication available.
Why it matters
By expanding access to the latest treatment delivery options, Ro is helping to make it easier for patients to manage their health and achieve their weight loss goals. The KwikPen provides a more user-friendly alternative to traditional injection methods, which could lead to improved medication adherence and better health outcomes.
The details
The Zepbound KwikPen is now available to cash-pay patients on Ro's platform, with transparent pricing starting at $299 per month for the 2.5 mg starter dose and $399 for the 5 mg dose. For higher doses, eligible patients can access manufacturer discounted pricing of $449 per month when refills are completed within 45 days. Patients can also use Ro's free GLP-1 Insurance Checker tool to understand their coverage and get the medication at the lowest possible price.
- Ro connected its platform with Eli Lilly's direct-to-patient offering in December 2024 to expand access to FDA-approved, authentic Zepbound.
- The Zepbound KwikPen was recently approved by the FDA and is now launching nationwide on Ro's platform.
The players
Ro
A leading direct-to-patient healthcare company with a mission of helping patients achieve their health goals through convenient, end-to-end healthcare services.
Eli Lilly
A pharmaceutical company that developed the Zepbound (tirzepatide) medication, the most effective GLP-1 treatment currently available.
Zepbound (tirzepatide)
The most effective GLP-1 medication on the market, now available in a new prefilled, multi-dose KwikPen form factor.
What they’re saying
“By working with Eli Lilly to make the KwikPen accessible on Ro's platform, we're continuing to help patients access the latest treatments, in the most innovative form factors, at the lowest possible cost.”
— Zach Reitano, Co-founder and CEO of Ro
The takeaway
Ro's partnership with Eli Lilly to launch the Zepbound KwikPen demonstrates the company's commitment to expanding access to the latest and most effective treatments, while also prioritizing patient convenience and affordability. This move could help more people manage their weight and achieve their health goals.
